(Q37048053)

17 August 2017

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors (English)

1 reference

17 August 2017

Nathalie Dhomen

22

0 references

Caroline J Springer

Caroline J Springer

48

0 references

Bartosz Chmielowski

Bartosz Chmielowski

47

0 references

Grant McArthur

Grant A McArthur

49

0 references

Richard Marais

Richard Marais

53

0 references

Gideon Bollag

5

Gideon Bollag

1 reference

17 August 2017

52

Antoni Ribas

1 reference

17 August 2017

33

Gaston Habets

1 reference

17 August 2017

10

Keith T Flaherty

1 reference

17 August 2017

32

Chao Zhang

1 reference

17 August 2017

7

Jorge S Reis-Filho

1 reference

17 August 2017

20

Maryou Lambros

1 reference

17 August 2017

50

Jeffrey A Sosman

1 reference

17 August 2017

37

Mark Kockx

1 reference

17 August 2017

Fei Su

1

1 reference

17 August 2017

Amaya Viros

2

1 reference

17 August 2017

Carla Milagre

3

1 reference

17 August 2017

Kerstin Trunzer

4

1 reference

17 August 2017

Olivia Spleiss

6

1 reference

17 August 2017

Xiangju Kong

8

1 reference

17 August 2017

Richard C Koya

9

1 reference

17 August 2017

Paul B Chapman

11

1 reference

17 August 2017

Min Jung Kim

12

1 reference

17 August 2017

Robert Hayward

13

1 reference

17 August 2017

Matthew Martin

14

1 reference

17 August 2017

Hong Yang

15

1 reference

17 August 2017

Qiongqing Wang

16

1 reference

17 August 2017

Holly Hilton

17

1 reference

17 August 2017

Julie S Hang

18

1 reference

17 August 2017

Johannes Noe

19

1 reference

17 August 2017

Felipe Geyer

21

1 reference

17 August 2017

Ion Niculescu-Duvaz

23

1 reference

17 August 2017

Alfonso Zambon

24

1 reference

17 August 2017

Dan Niculescu-Duvaz

25

1 reference

17 August 2017

Natasha Preece

26

1 reference

17 August 2017

Lídia Robert

27

1 reference

17 August 2017

Nicholas J Otte

28

1 reference

17 August 2017

Stephen Mok

29

1 reference

17 August 2017

Damien Kee

30

1 reference

17 August 2017

Yan Ma

31

1 reference

17 August 2017

Elizabeth A Burton

34

1 reference

17 August 2017

Bernice Wong

35

1 reference

17 August 2017

Hoa Nguyen

36

1 reference

17 August 2017

Luc Andries

38

1 reference

17 August 2017

Brian Lestini

39

1 reference

17 August 2017

Keith B Nolop

40

1 reference

17 August 2017

Richard J Lee

41

1 reference

17 August 2017

Andrew K Joe

42

1 reference

17 August 2017

James L Troy

43

1 reference

17 August 2017

Rene Gonzalez

44

1 reference

17 August 2017

Thomas E Hutson

45

1 reference

17 August 2017

Igor Puzanov

46

1 reference

17 August 2017

Roger S Lo

51

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 January 2012

1 reference

The New England Journal of Medicine

17 August 2017

1 reference

17 August 2017

366

1 reference

17 August 2017

207-215

1 reference

17 August 2017

3

1 reference

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Defining the origins of Ras/p53-mediated squamous cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

RalGDS is required for tumor formation in a model of skin carcinogenesis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Mutations of the BRAF gene in human cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Cutaneous squamous-cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Paradoxical activation of Raf by a novel Raf inhibitor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

DNA sequencing with chain-terminating inhibitors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Tumour biology: senescence in premalignant tumours

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Transformation of mouse skin endothelial cells in vivo by direct application of plasmid DNA encoding the human T24 H-ras oncogene

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Comparison of ras activation during epidermal carcinogenesis in vitro and in vivo

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

RAS oncogenes: the first 30 years.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724537

Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune response

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22256804

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1105358

1 reference

17 August 2017

1 reference

17 August 2017

1 reference